{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T16:34:23Z","timestamp":1792946063584,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jacadv.2026.103298","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:44:32Z","timestamp":1791179072000},"page":"103298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Ticagrelor Monotherapy or Aspirin Plus Prasugrel After Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-4025","authenticated-orcid":false,"given":"Michele","family":"Maremmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Citerni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4915-9501","authenticated-orcid":false,"given":"Ovidio","family":"De Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Menozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1734-6924","authenticated-orcid":false,"given":"Carlos M.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-9317","authenticated-orcid":false,"given":"Fabrizio","family":"D\u2019Ascenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Templin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Di Vece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jacadv.2026.103298_bib1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jacc.2007.02.028","article-title":"ACC\/AHA 2007 guidelines for the management of patients with unstable Angina\/Non\u2013ST-Elevation myocardial infarction","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103298_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.jacadv.2026.103298_bib3","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"9281","key":"10.1016\/j.jacadv.2026.103298_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jacadv.2026.103298_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacadv.2026.103298_bib6","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2026.103298_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/CIRCULATIONAHA.124.069012","article-title":"Demystifying the contemporary role of 12-Month dual antiplatelet therapy after acute coronary syndrome","volume":"150","author":"Valgimigli","year":"2024","journal-title":"Circulation"},{"issue":"10439","key":"10.1016\/j.jacadv.2026.103298_bib8","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103298_bib9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.jacadv.2026.103298_bib10","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.jacadv.2026.103298_bib11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacadv.2026.103298_bib12","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10456","key":"10.1016\/j.jacadv.2026.103298_bib13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials","volume":"404","author":"Valgimigli","year":"2024","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jacadv.2026.103298_bib14","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.jacc.2025.04.046","article-title":"The 2025 ACS guideline update endorses ticagrelor monotherapy \u22651 month after DAPT Post-PCI","volume":"85","author":"Mehran","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacadv.2026.103298_bib15","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103298_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2025.5057","article-title":"Ticagrelor vs prasugrel in patients with diabetes and multivessel coronary artery disease","author":"Bangalore","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103298_bib17","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2026.103298_bib18","series-title":"Cochrane handbook for systematic reviews of interventions Version 6.5","year":"2024"},{"key":"10.1016\/j.jacadv.2026.103298_bib19","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.jacadv.2026.103298_bib20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jacadv.2026.103298_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jacadv.2026.103298_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jacadv.2026.103298_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jacadv.2026.103298_bib24","author":"R\u00fccker"},{"key":"10.1016\/j.jacadv.2026.103298_bib25","author":"Harrer"},{"issue":"11","key":"10.1016\/j.jacadv.2026.103298_bib26","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamacardio.2019.3355","article-title":"Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes","volume":"4","author":"Tomaniak","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"37","key":"10.1016\/j.jacadv.2026.103298_bib27","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103298_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2026.1128","article-title":"Efficacy and safety of prasugrel, ticagrelor, or clopidogrel after percutaneous coronary intervention","author":"Maqsood","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103298_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehag381","article-title":"P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis","author":"Spagnolo","year":"2026","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacadv.2026.103298_bib30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamacardio.2024.3216","article-title":"Short-term dual antiplatelet therapy after drug-eluting stenting in patients with acute coronary syndromes","volume":"9","author":"Carvalho","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10.1016\/j.jacadv.2026.103298_bib31","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jcin.2020.07.032","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetes mellitus","volume":"13","author":"Ndrepepa","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.jacadv.2026.103298_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.jacadv.2026.103298_bib33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","author":"Ferreiro","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103298_bib34","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc12-2510","article-title":"Randomized assessment of ticagrelor versus Prasugrel antiplatelet effects in patients with diabetes","volume":"36","author":"Alexopoulos","year":"2013","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.jacadv.2026.103298_bib35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","article-title":"Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease","volume":"134","author":"Franchi","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacadv.2026.103298_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCINTERVENTIONS.113.000293","article-title":"Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with Non\u2013ST-Elevation acute coronary syndrome undergoing percutaneous coronary intervention","volume":"6","author":"Alexopoulos","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"issue":"23","key":"10.1016\/j.jacadv.2026.103298_bib37","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","article-title":"Adenosine-mediated effects of ticagrelor","volume":"63","author":"Cattaneo","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacadv.2026.103298_bib38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacc.2012.11.032","article-title":"Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans","volume":"61","author":"Wittfeldt","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacadv.2026.103298_bib39","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jcin.2017.05.064","article-title":"Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with Non\u2013ST-Segment elevation acute coronary syndrome requiring coronary stenting","volume":"10","author":"Jeong","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"10.1016\/j.jacadv.2026.103298_bib40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jacadv.2026.103298_bib41","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.4244\/EIJ-D-25-00331","article-title":"One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial","volume":"21","author":"Jang","year":"2025","journal-title":"EuroIntervention"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T15:50:42Z","timestamp":1792943442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26007209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2772963X26007209"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103298","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor Monotherapy or Aspirin Plus Prasugrel After Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103298"}}